{
    "clinical_study": {
        "@rank": "67202", 
        "arm_group": [
            {
                "arm_group_label": "Loteprednol Etabonate Gel (BID)", 
                "arm_group_type": "Experimental", 
                "description": "Loteprednol Etabonate Gel 0.38% administered two times daily (BID)."
            }, 
            {
                "arm_group_label": "Vehicle (BID)", 
                "arm_group_type": "Active Comparator", 
                "description": "Vehicle of Loteprednol Etabonate Gel 0.38% administered two times daily (BID)."
            }, 
            {
                "arm_group_label": "Loteprednol Etabonate Gel (TID)", 
                "arm_group_type": "Experimental", 
                "description": "Loteprednol Gel 0.38% administered three times daily (TID)."
            }, 
            {
                "arm_group_label": "Vehicle (TID)", 
                "arm_group_type": "Active Comparator", 
                "description": "Vehicle of Loteprednol Etabonate Gel 0.38% administered three times daily (TID)."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate\n      ophthalmic gel, 0.38% (BID and TID) for the treatment of postoperative inflammation and pain\n      following cataract surgery."
        }, 
        "brief_title": "Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Inflammation", 
            "Pain", 
            "Cataract"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Cataract"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Visit 1 (Screening Visit)\n\n          -  Be willing and able to comply with all treatment and follow-up/study procedures.\n\n          -  Be a candidate for routine, uncomplicated cataract surgery\n\n        Visit 3 (Postoperative Day 1)\n\n          -  Have undergone routine, uncomplicated cataract surgery (phaco- emulsification with\n             posterior chamber IOL implantation, not combined with any other surgery) in the study\n             eye.\n\n          -  Have \u2265\u2009Grade 2 anterior chamber (AC) cells (6-15 cells) in the study eye.\n\n        Exclusion Criteria:\n\n          -  Have a severe/serious ocular condition or history/presence of chronic generalized\n             systemic disease that the Investigator feels might increase the risk to the subject\n             or confound the result(s) of the study.\n\n          -  Have known hypersensitivity or contraindication to the study drug(s) or their\n             components."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "483", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996839", 
            "org_study_id": "842"
        }, 
        "intervention": [
            {
                "arm_group_label": "Loteprednol Etabonate Gel (BID)", 
                "description": "One drop of LE gel instilled into the study eye two times per day (BID) for 14 days", 
                "intervention_name": "Loteprednol Etabonate Gel (BID)", 
                "intervention_type": "Drug", 
                "other_name": "Lotemax"
            }, 
            {
                "arm_group_label": "Loteprednol Etabonate Gel (TID)", 
                "description": "One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.", 
                "intervention_name": "Loteprednol Etabonate Gel (TID)", 
                "intervention_type": "Drug", 
                "other_name": "Lotemax"
            }, 
            {
                "arm_group_label": "Vehicle (BID)", 
                "description": "One drop of vehicle instilled into the study eye two times per day (BID) for 14 days", 
                "intervention_name": "Vehicle (BID)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle (TID)", 
                "description": "One drop of vehicle instilled into the study eye three times per day (TID) for 14 days", 
                "intervention_name": "Vehicle (TID)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Loteprednol etabonate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07940"
                }, 
                "name": "Bausch & Lomb Incorporated"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery", 
        "other_outcome": [
            {
                "description": "Study drug sensation assessment", 
                "measure": "Drug Sensation", 
                "safety_issue": "No", 
                "time_frame": "Visit 5 (Postoperative Day 8)"
            }, 
            {
                "description": "Ocular symptoms", 
                "measure": "Ocular Symptoms", 
                "safety_issue": "No", 
                "time_frame": "At all study visits through Visit 7 (day 18)"
            }
        ], 
        "overall_contact": {
            "email": "robert.keaney@bausch.com", 
            "last_name": "Robert P Keaney, MSPH", 
            "phone": "949 789 3170"
        }, 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Jon I Williams, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Participants with complete resolution of anterior chamber (AC) cells (cell score\u2009=\u20090) in the study eye.", 
                "measure": "Resolution of AC Cells", 
                "safety_issue": "No", 
                "time_frame": "Visit 5 (Postoperative day 8)"
            }, 
            {
                "description": "Participants with Grade 0 pain in the study eye.", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "Visit 5 (Postoperative Day 8)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996839"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Participants with complete resolution of AC cells (cell score=0) in the study eye at each on-treatment visit.", 
                "measure": "Resolution of AC cells", 
                "safety_issue": "No", 
                "time_frame": "At each study visit through Visit 6 (day 15)"
            }, 
            {
                "description": "Participants with Grade 0 pain (no pain) in the study eye at each on-treatment visit.", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "At each study visit through Visit 6 (day 15)"
            }, 
            {
                "description": "Participants with complete resolution of AC flare in the study eye at each on-treatment visit.", 
                "measure": "Resolution of AC Flare", 
                "safety_issue": "No", 
                "time_frame": "At each study visit through Visit 6 (day 15)"
            }, 
            {
                "description": "Participants with complete resolution of AC cells and flare in the study eye at each on-treatment visit.", 
                "measure": "Resolution of AC Cells and Flare", 
                "safety_issue": "No", 
                "time_frame": "At each study visit through Visit 6 (day 15)"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}